Mission Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.68M Sell
7,048
-1,122
-14% -$575K 0.06% 191
2026
Q2
$4.06M Buy
8,170
+4,075
+100% +$1.81M 0.05% 202
2026
Q1
$1.83M Buy
4,095
+39
+1% +$18.2K 0.04% 227
2025
Q4
$1.84M Buy
4,056
+89
+2% +$38.4K 0.04% 224
2025
Q3
$1.55M Sell
3,967
-1,742
-31% -$728K 0.03% 250
2025
Q2
$2.54M Sell
5,709
-1,202
-17% -$554K 0.05% 185
2025
Q1
$3.35M Buy
6,911
+859
+14% +$400K 0.08% 136
2024
Q4
$2.44M Sell
6,052
-575
-9% -$267K 0.06% 163
2024
Q3
$3.08M Buy
6,627
+815
+14% +$391K 0.07% 138
2024
Q2
$2.72M Sell
5,812
-1,995
-26% -$866K 0.07% 144
2024
Q1
$3.26M Buy
7,807
+2,914
+60% +$1.23M 0.09% 130
2023
Q4
$1.99M Buy
4,893
+212
+5% +$78.3K 0.06% 148
2023
Q3
$1.63M Buy
4,681
+70
+2% +$24.5K 0.06% 157
2023
Q2
$1.62M Buy
4,611
+21
+0.5% +$7.08K 0.06% 154
2023
Q1
$1.45M Buy
4,590
+64
+1% +$19.2K 0.06% 171
2022
Q4
$1.31M Buy
4,526
+164
+4% +$50K 0.06% 167
2022
Q3
$1.26M Buy
4,362
+96
+2% +$27.6K 0.07% 156
2022
Q2
$1.2M Buy
4,266
+658
+18% +$176K 0.06% 168
2022
Q1
$942K Buy
3,608
+492
+16% +$117K 0.04% 211
2021
Q4
$684K Sell
3,116
-55
-2% -$10.7K 0.03% 250
2021
Q3
$575K Buy
3,171
+57
+2% +$11.1K 0.03% 261
2021
Q2
$628K Buy
3,114
+63
+2% +$13.2K 0.03% 250
2021
Q1
$656K Buy
3,051
+490
+19% +$108K 0.04% 211
2020
Q4
$605K Buy
2,561
+332
+15% +$76.2K 0.04% 196
2020
Q3
$607K Buy
2,229
+44
+2% +$12.1K 0.05% 170
2020
Q2
$634K Buy
2,185
+52
+2% +$14.1K 0.05% 159
2020
Q1
$508K Sell
2,133
-7
-0.3% -$1.61K 0.06% 160
2019
Q4
$469K Buy
2,140
+125
+6% +$25.3K 0.05% 189
2019
Q3
$341K Sell
2,015
-459
-19% -$81.2K 0.04% 212
2019
Q2
$454K Sell
2,474
-264
-10% -$46.2K 0.05% 181
2019
Q1
$504K Buy
2,738
+231
+9% +$42.7K 0.06% 169
2018
Q4
$415K Buy
2,507
+465
+23% +$80.6K 0.05% 170
2018
Q3
$394K Hold
2,042
– – 0.05% 176
2018
Q2
$347K Buy
+2,042
New +$317K 0.05% 177

Other funds holding VRTX

Mission Wealth Management's VRTX Position: Q3 2026 in Review

Mission Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q3 2026, selling an estimated $575K and leaving 7,048 shares worth $3.68M. The position accounts for 0.06% of the portfolio, ranked #191.

Mission Wealth Management first reported a position in VRTX in Q2 2018 and has held it in 34 quarters since. The position peaked at $4.06M in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Mission Wealth Management held 7,048 shares of Vertex Pharmaceuticals worth $3.68M as of Q3 2026.
  • Mission Wealth Management sold 1,122 Vertex Pharmaceuticals shares in Q3 2026, an estimated $575K.
  • Vertex Pharmaceuticals made up 0.06% of Mission Wealth Management's portfolio in Q3 2026, its #191 holding.
  • Mission Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 34 quarters since.
  • Mission Wealth Management's Vertex Pharmaceuticals position peaked at $4.06M in Q2 2026.
  • 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Mission Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.